2026-09-21T21:07:09Zhttps://wakespace.lib.wfu.edu/server/oai/request

oai:null:10339/822052026-09-02T13:01:03Zcom_10339_14934col_10339_38132

Swanner, Jessica Lynn 2017-06-15T08:35:59Z 2018-06-14T08:30:10Z 2017 https://wakespace.lib.wfu.edu/handle/10339/82205 A woman’s lifetime risk of being diagnosed with breast cancer is approximately 1 in 8, and it is estimated that over 40,000 women will die from BC in 2017. With advances in molecular profiling, breast cancer has been divided into 5 molecular subtypes (luminal A, luminal B, HER-2 overexpressing, basal-like, and claudin-low) that have distinct genetic aberrations, morphological features, prognoses, and therapeutic responses. Therefore, breast cancer should be treated with subtype specific therapies as these may provide the greatest therapeutic benefit. en Wake Forest University breast cancer nanomaterials novel therapeutics reactive oxygen species silver SILVER NANOPARTICLES ARE EFFECTIVE FOR THE TREATMENT OF CLAUDIN LOW BREAST CANCER AND OTHER MESENCHYMAL CANCERS WITH HIGH ZEB1 EXPRESSION Dissertation Singh, Ravi N Kridel, Steven J Kucera, Gregory L Metheny-Barlow, Linda J Cancer Biology 2018-06-14 open.access